Q BioMed Inc
Change company Symbol lookup
Select an option...
QBIO Q BioMed Inc
FTDR Frontdoor Inc
HD Home Depot Inc
SRCE 1st Source Corp
PNC PNC Financial Services Group Inc
AAPL Apple Inc
MSFT Microsoft Corp
FAZE FaZe Holdings Inc
SSP E W Scripps Co
NHWK NightHawk Biosciences Inc
Go

Health Care : Biotechnology |
Company profile

Q BioMed Inc. is a biotech acceleration and commercial stage company. The Company is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Company’s pipeline products include Strontium89, QBM-001, Uttroside-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated for the relief of bone pain in patients with painful skeletal metastases. QBM-001 is designed to alleviate the condition and allow toddlers to actively develop language and speech and avoid life-long speech and intellectual disabilities caused from being non-verbal. Uttroside-B is a potential chemotherapeutic for liver cancer. Its primary indication, MAN-01, is for the treatment of primary open angle glaucoma, wherein it is developing a small molecule in the form of an easy to administer eye drop to reduce intra-ocular eye pressure (IOP), a key risk factor in the progression of glaucoma.

Price
Delayed
$0.0006
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.0006
Day's Low
0.0006
Volume
(Light)

Today's volume of 100 shares is on pace to be much lighter than QBIO's 10-day average volume of 1,896 shares.

100

There are no calendar events for QBIO

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.